Reporter Dai Yuxiang / Taipei Report
—
Polaris Pharmaceuticals-KY (6550) was suspended from trading yesterday (21) and held a press conference for re-information. In the afternoon, President Chen Hongwen announced that the third phase of the new mesothelial lung cancer drug was successful! Incentive opened today (22) to exceed the daily limit, the share price reached 215 yuan and the number of entrusted purchases reached 26,000.
Polaris Pharmaceuticals-KY (6550) announced on the 21st that the results of the global multi-country, multi-center Phase III clinical trial of its new drug for the treatment of mesothelial lung cancer (ADI-PEG20) are under development, according to the results of the non-blinded data, showed that the main measure of efficacy was to prolong lung cancer. Overall survival (OS) and progression-free survival of patients with mesothelial carcinoma were statistically significant and unmasking was officially successfully announced.
Polaris Pharmaceuticals said the ADI-PEG 20 developed by the company is different from chemotherapy, from the targeted immunotherapy currently used by most people in the treatment of cancer, but it uses metabolic therapy and combination therapy for treatment. ADI-PEG20 is a new highly effective anticancer drug for metabolic therapy. Hundreds of articles have been published on research into the treatment of various cancer indications in leading medical centers around the world. Therefore, Polaris Pharmaceuticals obtained the FDA’s first drug formula with AD I -PEG20 will become a synthetic drug, the new anticancer drugs are of great importance.
Polaris Pharmaceuticals stressed that the company will use the FDA’s accelerated review qualification to actively accelerate the drug application process. ADI-PEG20’s success in treating mesothelial lung cancer is just the beginning of ADI’s use. PEG20 in cancer metabolic therapy. Phase III follow-up studies for liver cancer, phase III studies for soft tissue tumors and phase 2/3 studies for brain tumors will continue. fatty liver and diabetes, will be carried out pragmatically, with the aim of making ADI-PEG20 the drug of choice for metabolic therapy, allowing more patients to benefit from it.
More articles from Sanli News
Exclusive / What Happens After Taiwan and US Raise Interest Rates? Experts Reveal Next Step for Taiwan Stocks: Expected to Usher in Major Counterattack
Exclusive / USA Rate Increase Coming! Taiwan shares staged “script”? Experts reveal a complete stop sign
The emperor shouted “3 words” on the battlefield! The 3,000 enemy troops under the king of Langya were frightened and fled
The Qing dynasty fell for more than 100 years! Are there still “grave guards”? In the past, there were only 3 types of people who could take responsibility
–
